Skip to main content
SpringerLink
Log in

Current Progress in Adoptive T-Cell Therapy of Lymphoma

  • Chapter
  • First Online:
Innate Immune Regulation and Cancer Immunotherapy

  • 1753 Accesses

Abstract

The lymphomas are a diverse group of malignancies arising from the lymphoreticular system. Individual subtypes have unique pathological features, clinical courses, and response to traditional chemotherapy agents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Andersen MH, Svane IM, Kvistborg P et al (2005) Immunogenicity of Bcl-2 in patients with cancer. Blood 105:728–734

    Article  PubMed  CAS  Google Scholar 

  • Armstrong AC, Dermime S, Mulryan K, Stern PL, Bhattacharyya T, Hawkins RE (2004) Adoptive transfer of anti-idiotypic T cells cure mice of disseminated B cell lymphoma. J Immunother 27:227–231

    Article  PubMed  Google Scholar 

  • Awwad M, North RJ (1988) Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology 65:87–92

    PubMed  CAS  Google Scholar 

  • Berger C, Blau CA, Huang ML et al (2004) Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood 103:1261–1269

    Article  PubMed  CAS  Google Scholar 

  • Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR (2008) Adoptive transfer of effector CD8± T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 118:294–305

    Article  PubMed  CAS  Google Scholar 

  • Bishop MR, Dean RM, Steinberg SM et al (2008) Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol 19:1935–1940

    Article  PubMed  CAS  Google Scholar 

  • Bollard CM, Rossig C, Calonge MJ et al (2002) Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 99:3179–3187

    Article  PubMed  CAS  Google Scholar 

  • Bollard CM, Aguilar L, Straathof KC et al (2004) Cytotoxic T lymphocyte therapy for Epstein-Barr virus± Hodgkin’s disease. J Exp Med 200:1623–1633

    Article  PubMed  CAS  Google Scholar 

  • Bollard CM, Gottschalk S, Huls MH et al (2006) In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma 47:837–842

    Article  PubMed  Google Scholar 

  • Bollard CM, Gottschalk S, Leen AM et al (2007) Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110:2838–2845

    Article  PubMed  CAS  Google Scholar 

  • Bonini C, Ferrari G, Verzeletti S et al (1997) HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276:1719–1724

    Article  PubMed  CAS  Google Scholar 

  • Brentjens RJ, Latouche JB, Santos E et al (2003) Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 9:279–286

    Article  PubMed  CAS  Google Scholar 

  • Chambost H, Van Baren N, Brasseur F et al (2000) Expression of gene MAGE-A4 in Reed-Sternberg cells. Blood 95:3530–3533

    PubMed  CAS  Google Scholar 

  • Chamoto K, Tsuji T, Funamoto H et al (2004) Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res 64:386–390

    Article  PubMed  CAS  Google Scholar 

  • Chaperot L, Delfau-Larue MH, Jacob MC et al (1999) Differentiation of antitumor-specific cytotoxic T lymphocytes from autologous tumor infiltrating lymphocytes in non-Hodgkin’s lymphomas. Exp Hematol 27:1185–1193

    Article  PubMed  CAS  Google Scholar 

  • Cheadle EJ, Gilham DE, Thistlethwaite FC, Radford JA, Hawkins RE (2005) Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells. Br J Haematol 129:322–332

    Article  PubMed  CAS  Google Scholar 

  • Cheadle EJ, Hawkins RE, Batha H, Rothwell DG, Ashton G, Gilham DE (2009) Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4± and CD8± T cells. J Immunother 32:207–218

    Article  PubMed  Google Scholar 

  • Cho HI, Hong YS, Lee MA et al (2006) Adoptive transfer of Epstein-Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas. Int J Hematol 83:66–73

    Article  PubMed  Google Scholar 

  • Circosta P, Granziero L, Follenzi A et al (2009) T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR. Hum Gene Ther 20(12):1576–1588

    Article  PubMed  CAS  Google Scholar 

  • Colleoni GW, Capodieci P, Tickoo S, Cossman J, Filippa DA, Ladanyi M (2002) Expression of SSX genes in the neoplastic cells of Hodgkin’s lymphoma. Hum Pathol 33:496–502

    Article  PubMed  CAS  Google Scholar 

  • Comoli P, Labirio M, Basso S et al (2002) Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 99:2592–2598

    Article  PubMed  CAS  Google Scholar 

  • Comoli P, Maccario R, Locatelli F et al (2005) Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant 5:1415–1422

    Article  PubMed  Google Scholar 

  • Comoli P, Basso S, Zecca M et al (2007) Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant 7:1648–1655

    Article  PubMed  CAS  Google Scholar 

  • Comoli P, Basso S, Labirio M, Baldanti F, Maccario R, Locatelli F (2008) T cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant. Blood Cells Mol Dis 40:68–70

    Article  PubMed  CAS  Google Scholar 

  • Cooper LJ, Topp MS, Serrano LM et al (2003) T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 101:1637–1644

    Article  PubMed  CAS  Google Scholar 

  • Cooper LJ, Ausubel L, Gutierrez M et al (2006) Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma. Cytotherapy 8:105–117

    Article  PubMed  CAS  Google Scholar 

  • Curtis RE, Travis LB, Rowlings PA et al (1999) Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 94:2208–2216

    PubMed  CAS  Google Scholar 

  • De Smet C, Lurquin C, Lethe B, Martelange V, Boon T (1999) DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 19:7327–7335

    PubMed  Google Scholar 

  • Dudley ME, Wunderlich JR, Robbins PF et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850–854

    Article  PubMed  CAS  Google Scholar 

  • Dudley ME, Wunderlich JR, Yang JC et al (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346–2357

    Article  PubMed  CAS  Google Scholar 

  • Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS (2003) Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 101:640–648

    Article  PubMed  CAS  Google Scholar 

  • Emanuel DJ, Lucas KG, Mallory GB Jr et al (1997) Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes. Transplantation 63:1691–1694

    Article  PubMed  CAS  Google Scholar 

  • Eshhar Z, Waks T, Gross G, Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90:720–724

    Article  PubMed  CAS  Google Scholar 

  • Finney HM, Lawson AD, Bebbington CR, Weir AN (1998) Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 161:2791–2797

    PubMed  CAS  Google Scholar 

  • Gandhi MK, Wilkie GM, Dua U et al (2007) Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. Am J Transplant 7:1293–1299

    Article  PubMed  CAS  Google Scholar 

  • Gattei V, Fonsatti E, Sigalotti L et al (2005) Epigenetic immunomodulation of hematopoietic malignancies. Semin Oncol 32:503–510

    Article  PubMed  CAS  Google Scholar 

  • Gottschalk S, Ng CY, Perez M et al (2001) An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 97:835–843

    Article  PubMed  CAS  Google Scholar 

  • Groeper C, Gambazzi F, Zajac P et al (2007) Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Int J Cancer 120:337–343

    Article  PubMed  CAS  Google Scholar 

  • Gross G, Waks T, Eshhar Z (1989) Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 86:10024–10028

    Article  PubMed  CAS  Google Scholar 

  • Gustafsson A, Levitsky V, Zou JZ et al (2000) Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 95:807–814

    PubMed  CAS  Google Scholar 

  • Hagihara M, Tsuchiya T, Hyodo O et al (2003) Clinical effects of infusing anti-Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes into patients with severe chronic active EBV infection. Int J Hematol 78:62–68

    Article  PubMed  Google Scholar 

  • Haque T, Amlot PL, Helling N et al (1998) Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. J Immunol 160:6204–6209

    PubMed  CAS  Google Scholar 

  • Haque T, Taylor C, Wilkie GM et al (2001) Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation 72:1399–1402

    Article  PubMed  CAS  Google Scholar 

  • Haque T, Wilkie GM, Taylor C et al (2002) Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 360:436–442

    Article  PubMed  Google Scholar 

  • Haque T, Wilkie GM, Jones MM et al (2007) Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110:1123–1131

    Article  PubMed  CAS  Google Scholar 

  • Harig S, Witzens M, Krackhardt AM et al (2001) Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues. Blood 98:2999–3005

    Article  PubMed  CAS  Google Scholar 

  • Heemskerk MH, Griffioen M, Falkenburg JH (2008) T-cell receptor gene transfer for treatment of leukemia. Cytotherapy 10:108–115

    Article  PubMed  CAS  Google Scholar 

  • Heslop HE (2009) How I treat EBV lymphoproliferation. Blood 114:4002–4008

    Article  PubMed  CAS  Google Scholar 

  • Heslop HE, Brenner MK, Rooney CM (1994) Donor T cells to treat EBV-associated lymphoma. N Engl J Med 331:679–680

    Article  PubMed  CAS  Google Scholar 

  • Heslop HE, Ng CY, Li C et al (1996) Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2:551–555

    Article  PubMed  CAS  Google Scholar 

  • Heslop HE, Slobod KS, Pule MA et al (2010) Long term outcome of EBV specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115(5):925–935

    Article  PubMed  CAS  Google Scholar 

  • Hombach A, Heuser C, Sircar R et al (1998) An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin’s lymphoma cells in the presence of soluble CD30. Cancer Res 58:1116–1119

    PubMed  CAS  Google Scholar 

  • Hong R, Shen V, Rooney C et al (2001) Correction of DiGeorge anomaly with EBV-induced lymphoma by transplantation of organ-cultured thymus and Epstein-Barr-specific cytotoxic T lymphocytes. Clin Immunol 98:54–61

    Article  PubMed  CAS  Google Scholar 

  • Hoogendoorn M, Wolbers JO, Smit WM et al (2004) Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy. Leukemia 18:1278–1287

    Article  PubMed  CAS  Google Scholar 

  • Hoogendoorn M, Olde Wolbers J, Smit WM et al (2005) Primary allogeneic T-cell responses against mantle cell lymphoma antigen-presenting cells for adoptive immunotherapy after stem cell transplantation. Clin Cancer Res 11:5310–5318

    Article  PubMed  CAS  Google Scholar 

  • Huang X, Guo H, Kang J et al (2008) Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19± lymphoid malignancies. Mol Ther 16:580–589

    Article  PubMed  CAS  Google Scholar 

  • Huls MH, Rooney CM, Heslop HE (2003) Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin’s disease. Acta Haematol 110:149–153

    Article  PubMed  Google Scholar 

  • Hwu P, Shafer GE, Treisman J et al (1993) Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med 178:361–366

    Article  PubMed  CAS  Google Scholar 

  • Imashuku S, Goto T, Matsumura T et al (1997) Unsuccessful CTL transfusion in a case of post-BMT Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD). Bone Marrow Transplant 20:337–340

    Article  PubMed  CAS  Google Scholar 

  • James SE, Greenberg PD, Jensen MC et al (2008) Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol 180:7028–7038

    PubMed  CAS  Google Scholar 

  • Jensen M, Tan G, Forman S, Wu AM, Raubitschek A (1998) CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20± malignancy. Biol Blood Marrow Transplant 4:75–83

    Article  PubMed  CAS  Google Scholar 

  • Jurgens LA, Khanna R, Weber J, Orentas RJ (2006) Transduction of primary lymphocytes with Epstein-Barr virus (EBV) latent membrane protein-specific T-cell receptor induces lysis of virus-infected cells: a novel strategy for the treatment of Hodgkin’s disease and nasopharyngeal carcinoma. J Clin Immunol 26:22–32

    Article  PubMed  CAS  Google Scholar 

  • Kalos M, Levine BL et al (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95):95ra73

    Article  PubMed  CAS  Google Scholar 

  • Khanna R, Bell S, Sherritt M et al (1999) Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA 96:10391–10396

    Article  PubMed  CAS  Google Scholar 

  • Khouri IF, McLaughlin P, Saliba RM et al (2008) Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111:5530–5536

    Article  PubMed  CAS  Google Scholar 

  • Kowolik CM, Topp MS, Gonzalez S et al (2006) CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 66:10995–11004

    Article  PubMed  CAS  Google Scholar 

  • Krause A, Guo HF, Latouche JB, Tan C, Cheung NK, Sadelain M (1998) Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med 188:619–626

    Article  PubMed  CAS  Google Scholar 

  • Kuwana Y, Asakura Y, Utsunomiya N et al (1987) Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun 149:960–968

    Article  PubMed  CAS  Google Scholar 

  • Kuzushima K, Yamamoto M, Kimura H et al (1996) Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection. Clin Exp Immunol 103:192–198

    Article  PubMed  CAS  Google Scholar 

  • Lamers CH, Sleijfer S, Vulto AG et al (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24:e20–e22

    Article  PubMed  Google Scholar 

  • Leshem B, Dorfman Y, Kedar E (1999) Induction of preferential cytotoxicity against allogeneic mouse lymphoma cells: in vitro and in vivo studies. Cancer Immunol Immunother 48:179–188

    Article  PubMed  CAS  Google Scholar 

  • Lucas KG, Salzman D, Garcia A, Sun Q (2004) Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer 100:1892–1901

    Article  PubMed  Google Scholar 

  • Mandigers CM, Verdonck LF, Meijerink JP, Dekker AW, Schattenberg AV, Raemaekers JM (2003) Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant 32:1159–1163

    Article  PubMed  CAS  Google Scholar 

  • Merlo A, Turrini R, Dolcetti R, Zanovello P, Amadori A, Rosato A (2008) Adoptive cell therapy against EBV-related malignancies: a survey of clinical results. Expert Opin Biol Ther 8:1265–1294

    Article  PubMed  CAS  Google Scholar 

  • Milone MC, Fish JD, Carpenito C et al (2009) Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17:1453–1464

    Article  PubMed  CAS  Google Scholar 

  • Mitsuyasu RT, Anton PA, Deeks SG et al (2000) Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(±) and CD8(±) T cells in human immunodeficiency virus-infected subjects. Blood 96:785–793

    PubMed  CAS  Google Scholar 

  • Mohty M, Isnardon D, Charbonnier A et al (2002) Generation of potent T(h)1 responses from patients with lymphoid malignancies after differentiation of B lymphocytes into dendritic-like cells. Int Immunol 14:741–750

    Article  PubMed  CAS  Google Scholar 

  • Morgan RA, Dudley ME, Wunderlich JR et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126–129

    Article  PubMed  CAS  Google Scholar 

  • O’Connor OA, Heaney ML, Schwartz L et al (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24:166–173

    Article  PubMed  CAS  Google Scholar 

  • O’Reilly RJ, Doubrovina E, Trivedi D, Hasan A, Kollen W, Koehne G (2007) Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants. Immunol Res 38:237–250

    Article  PubMed  CAS  Google Scholar 

  • Opelz G, Dohler B (2004) Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 4:222–230

    Article  PubMed  Google Scholar 

  • Orentas RJ, Roskopf SJ, Nolan GP, Nishimura MI (2001) Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. Clin Immunol 98:220–228

    Article  PubMed  CAS  Google Scholar 

  • Pakakasama S, Eames GM, Morriss MC et al (2004) Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation 78:755–757

    Article  PubMed  Google Scholar 

  • Pallesen G, Hamilton-Dutoit SJ, Zhou X (1993) The association of Epstein-Barr virus (EBV) with T cell lymphoproliferations and Hodgkin’s disease: two new developments in the EBV field. Adv Cancer Res 62:179–239

    Article  PubMed  CAS  Google Scholar 

  • Papadopoulos EB, Ladanyi M, Emanuel D et al (1994) Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330:1185–1191

    Article  PubMed  CAS  Google Scholar 

  • Paya CV, Fung JJ, Nalesnik MA et al (1999) Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and the Mayo Clinic Organized International Consensus Development Meeting. Transplantation 68:1517–1525

    Article  PubMed  CAS  Google Scholar 

  • Porter DL, Levine BL et al (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365(8):725–733

    Article  PubMed  CAS  Google Scholar 

  • Pule MA, Savoldo B, Myers GD et al (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14:1264–1270

    Article  PubMed  CAS  Google Scholar 

  • Quintarelli C, Vera JF, Savoldo B et al (2007) Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 110:2793–2802

    Article  PubMed  CAS  Google Scholar 

  • Riddell SR (2007) Engineering antitumor immunity by T-cell adoptive immunotherapy. Hematology Am Soc Hematol Educ Program 250–256

    Google Scholar 

  • Riddell SR, Elliott M, Lewinsohn DA et al (1996) T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 2:216–223

    Article  PubMed  CAS  Google Scholar 

  • Rooney CM, Smith CA, Ng CY et al (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9–13

    Article  PubMed  CAS  Google Scholar 

  • Rooney CM, Smith CA, Ng CY et al (1998a) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92:1549–1555

    PubMed  CAS  Google Scholar 

  • Rooney CM, Heslop HE, Brenner MK (1998b) EBV specific CTL: a model for immune therapy. Vox Sang 74(Suppl 2):497–498

    Article  PubMed  CAS  Google Scholar 

  • Rooney CM, Bollard C, Huls MH et al (2002) Immunotherapy for Hodgkin’s disease. Ann Hematol 81(Suppl 2):S39–S42

    PubMed  CAS  Google Scholar 

  • Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318–1321

    Article  PubMed  CAS  Google Scholar 

  • Roskrow MA, Suzuki N, Gan Y et al (1998) Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin’s disease. Blood 91:2925–2934

    PubMed  CAS  Google Scholar 

  • Rossig C, Pscherer S, Landmeier S, Altvater B, Jurgens H, Vormoor J (2005) Adoptive cellular immunotherapy with CD19-specific T cells. Klin Padiatr 217:351–356

    Article  PubMed  CAS  Google Scholar 

  • Sackstein R (2005) The lymphocyte homing receptors: gatekeepers of the multistep paradigm. Curr Opin Hematol 12:444–450

    Article  PubMed  Google Scholar 

  • Savoldo B, Huls MH, Liu Z et al (2002) Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 100:4059–4066

    Article  PubMed  CAS  Google Scholar 

  • Savoldo B, Goss JA, Hammer MM et al (2006) Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 108:2942–2949

    Article  PubMed  CAS  Google Scholar 

  • Savoldo B, Rooney CM, Di Stasi A et al (2007) Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 110:2620–2630

    Article  PubMed  CAS  Google Scholar 

  • Savoldo B, Ramos CA, et al (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121(5):1822–1826

    Article  PubMed  CAS  Google Scholar 

  • Schmitter D, Bolliger U, Hallek M, Pichert G (1999) Involvement of the CD27-CD70 co-stimulatory pathway in allogeneic T-cell response to follicular lymphoma cells. Br J Haematol 106:64–70

    Article  PubMed  CAS  Google Scholar 

  • Serrano LM, Pfeiffer T, Olivares S et al (2006) Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. Blood 107:2643–2652

    Article  PubMed  CAS  Google Scholar 

  • Shafer JA, Leen AM, Cruz CR et al (2008) The “side-population” of human lymphoma cells have increased chemo-resistance, stem-cell like properties and are potential targets for immunotherapy. ASH Annu Meet Abstr 112:2620

    Google Scholar 

  • Sharpe AH (2009) Mechanisms of costimulation. Immunol Rev 229:5–11

    Article  PubMed  CAS  Google Scholar 

  • Sherritt MA, Bharadwaj M, Burrows JM et al (2003) Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation 75:1556–1560

    Article  PubMed  Google Scholar 

  • Shichijo S, Yamada A, Sagawa K et al (1996) Induction of MAGE genes in lymphoid cells by the demethylating agent 5-aza-2′-deoxycytidine. Jpn J Cancer Res 87:751–756

    Article  PubMed  CAS  Google Scholar 

  • Straathof KC, Pule MA, Yotnda P et al (2005) An inducible caspase 9 safety switch for T-cell therapy. Blood 105:4247–4254

    Article  PubMed  CAS  Google Scholar 

  • Sun Q, Burton R, Reddy V, Lucas KG (2002) Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. Br J Haematol 118:799–808

    Article  PubMed  Google Scholar 

  • Thomis DC, Marktel S, Bonini C et al (2001) A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 97:1249–1257

    Article  PubMed  CAS  Google Scholar 

  • Thorley-Lawson DA, Gross A (2004) Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350:1328–1337

    Article  PubMed  CAS  Google Scholar 

  • Thorley-Lawson DA, Duca KA, Shapiro M (2008) Epstein-Barr virus: a paradigm for persistent infection – for real and in virtual reality. Trends Immunol 29:195–201

    Article  PubMed  CAS  Google Scholar 

  • Till BG, Jensen MC, Wang J et al (2008) Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112:2261–2271

    Article  PubMed  CAS  Google Scholar 

  • Tsao L, Hsi ED (2007) The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med 131:1209–1218

    PubMed  Google Scholar 

  • Vera J, Savoldo B, Vigouroux S et al (2006) T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 108:3890–3897

    Article  PubMed  CAS  Google Scholar 

  • Wagner HJ, Cheng YC, Huls MH et al (2004) Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 103:3979–3981

    Article  PubMed  CAS  Google Scholar 

  • Walker RE, Bechtel CM, Natarajan V et al (2000) Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 96:467–474

    PubMed  CAS  Google Scholar 

  • Wang J, Jensen M, Lin Y et al (2007) Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther 18:712–725

    Article  PubMed  CAS  Google Scholar 

  • Wynn RF, Arkwright PD, Haque T et al (2005) Treatment of Epstein-Barr-virus-associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantation. Lancet Oncol 6:344–346

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children’s Hospital, Houston, TX, USA

    Kenneth P. Micklethwaite, Helen E. Heslop & Malcolm K. Brenner

Authors
  1. Kenneth P. Micklethwaite
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helen E. Heslop
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Malcolm K. Brenner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Malcolm K. Brenner .

Editor information

Editors and Affiliations

  1. Center for Cell & Gene Therapy, Baylor College of Medicine, Baylor Plaza 1, Houston, 77030, Texas, USA

    Rongfu Wang

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Micklethwaite, K.P., Heslop, H.E., Brenner, M.K. (2012). Current Progress in Adoptive T-Cell Therapy of Lymphoma. In: Wang, R. (eds) Innate Immune Regulation and Cancer Immunotherapy. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-9914-6_23

Download citation

Publish with us

Policies and ethics

Search

Navigation